Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients

Gu, Tengfei; Li, Jie; Chen, Ting; Zhu, Qingfeng; Ding, Jiafeng

doi:10.1007/s11255-023-03481-9

Cited by 1 publication

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abiraterone can also affect the function of androgen receptors. Studies have confirmed that abiraterone can reduce the nuclear translocation of the androgen receptor and the binding of Deoxyribonucleic Acid (DNA), thereby reducing the transcriptional activity of androgen [14] . Studies have also shown that abiraterone can increase the degradation of androgen receptor and inhibit the phosphorylation of androgen receptor [15] .…”

Section: Resultsmentioning

confidence: 99%

Comparative Study on the Effect of Docetaxel and Abiraterone in the Treatment of Metastatic Castration Resistant Prostate Cancer

Ma,

Chen

2024

IJPS

View full text Add to dashboard Cite

The study explored to evaluate and compare the effect of docetaxel and abiraterone in the treatment of metastatic castration resistant prostate cancer. 40 metastatic castration-resistant prostate cancer patients were retrospectively analysed and were divided into 2 groups, A and B each of 20 individuals (n=20). Group A was treated with docetaxel+prednisone tablets, and group B was treated with abiraterone+prednisone tablets. After the treatment, the treatment effects, progression-free survival, 1 y survival rate, tumor marker index levels, residual urine volume, maximum flow rate of urine, testosterone, and prostate-specific levels before and after treatment were compared between the two groups. Prostate specific antigen and androgen receptor splice variant-7 levels were compared to evaluate the safety of the two groups. The total effective rate in group B was 85 %, which was significantly higher than that in group A (p<0.05). The progression-free survival in group B was 13.2 mo, while in group A it was 10.2 mo (p<0.05). There was no significant difference in 1 y survival rate between the two groups (p>0.05). The levels of tumor markers in group B were lower than those in group A (p<0.05). The reduction of residual urine volume in group B was higher than that in group A (p<0.05), and maximum flow rate was greater in group A than in group B (p<0.05). The levels of testosterone, prostate specific antigen and androgen receptor splice variant-7 were lower in group B than those in group A (p<0.05). The adverse reaction rate of group B was 15 % lower than that of group A (35 %) (p<0.05). Abiraterone has a good clinical effect, can effectively improve the clinical symptoms of patients, with high drug safety, and is worthy of promotion.

show abstract

Section: Resultsmentioning

confidence: 99%